TTM
$63.31B
YoY change
-1.6%
5Y CAGR
+8.5%
Peak year (2022)
$100.33B
Cumulative revenue
$1.52T
Revenue history chart for Pfizer (PFE) from 1985 to 2025
Latest: $62.58B
Revenue growth chart for Pfizer (PFE) from 1985 to 2025
Latest: -1.6%
Revenue history table for Pfizer (PFE) from 1985 to 2025
| 2025 | $62.58B | -1.6% | −$1.05B | ||
| 2024 | $63.63B | +6.8% | +$4.07B | ||
| 2023 | $59.55B | -40.6% | −$40.78B | ||
| 2022 | $100.33B | +23.4% | +$19.04B | ||
| 2021 | $81.29B | +95.2% | +$39.64B | ||
| 2020 | $41.65B | +1.2% | +$479.00M | ||
| 2019 | $41.17B | -23.3% | −$12.47B | ||
| 2018 | $53.65B | +2.1% | +$1.10B | ||
| 2017 | $52.55B | -0.5% | −$278.00M | ||
| 2016 | $52.82B | +8.1% | +$3.97B | ||
| 2015 | $48.85B | -1.5% | −$754.00M | ||
| 2014 | $49.60B | -3.8% | −$1.98B | ||
| 2013 | $51.58B | -5.6% | −$3.07B | ||
| 2012 | $54.66B | -10.4% | −$6.38B | ||
| 2011 | $61.03B | -9.0% | −$6.02B | ||
| 2010 | $67.06B | +34.1% | +$17.05B | ||
| 2009 | $50.01B | +3.5% | +$1.71B | ||
| 2008 | $48.30B | -0.3% | −$132.00M | ||
| 2007 | $48.43B | +0.1% | +$57.00M | ||
| 2006 | $48.37B | +2.0% | +$966.00M | ||
| 2005 | $47.41B | -9.7% | −$5.11B | ||
| 2004 | $52.52B | +16.2% | +$7.33B | ||
| 2003 | $45.19B | +39.6% | +$12.81B | ||
| 2002 | $32.37B | +0.4% | +$114.00M | ||
| 2001 | $32.26B | +9.1% | +$2.69B | ||
| 2000 | $29.57B | +82.5% | +$13.37B | ||
| 1999 | $16.20B | +19.6% | +$2.66B | ||
| 1998 | $13.54B | +8.3% | +$1.04B | ||
| 1997 | $12.50B | +10.6% | +$1.20B | ||
| 1996 | $11.31B | +12.8% | +$1.28B | ||
| 1995 | $10.02B | +21.0% | +$1.74B | ||
| 1994 | $8.28B | +10.7% | +$803.60M | ||
| 1993 | $7.48B | +3.4% | +$247.50M | ||
| 1992 | $7.23B | +4.0% | +$280.20M | ||
| 1991 | $6.95B | +8.5% | +$544.00M | ||
| 1990 | $6.41B | +13.0% | +$734.50M | ||
| 1989 | $5.67B | +5.3% | +$286.10M | ||
| 1988 | $5.39B | +9.5% | +$465.60M | ||
| 1987 | $4.92B | +9.9% | +$443.80M | ||
| 1986 | $4.48B | +11.2% | +$451.50M | ||
| 1985 | $4.02B | — | — |
- 2025$62.58B-1.6%
- 2024$63.63B+6.8%
- 2023$59.55B-40.6%
- 2022$100.33B+23.4%
- 2021$81.29B+95.2%
- 2020$41.65B+1.2%
- 2019$41.17B-23.3%
- 2018$53.65B+2.1%
- 2017$52.55B-0.5%
- 2016$52.82B+8.1%
- 2015$48.85B-1.5%
- 2014$49.60B-3.8%
- 2013$51.58B-5.6%
- 2012$54.66B-10.4%
- 2011$61.03B-9.0%
- 2010$67.06B+34.1%
- 2009$50.01B+3.5%
- 2008$48.30B-0.3%
- 2007$48.43B+0.1%
- 2006$48.37B+2.0%
- 2005$47.41B-9.7%
- 2004$52.52B+16.2%
- 2003$45.19B+39.6%
- 2002$32.37B+0.4%
- 2001$32.26B+9.1%
- 2000$29.57B+82.5%
- 1999$16.20B+19.6%
- 1998$13.54B+8.3%
- 1997$12.50B+10.6%
- 1996$11.31B+12.8%
- 1995$10.02B+21.0%
- 1994$8.28B+10.7%
- 1993$7.48B+3.4%
- 1992$7.23B+4.0%
- 1991$6.95B+8.5%
- 1990$6.41B+13.0%
- 1989$5.67B+5.3%
- 1988$5.39B+9.5%
- 1987$4.92B+9.9%
- 1986$4.48B+11.2%
- 1985$4.02B—
Revenue values are taken from Pfizer's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Revenue at Pfizer (PFE)
According to Pfizer's latest reported financial statements, the company's current revenue (TTM) is $63.31B. Revenue is the total income from selling goods or services before any expenses. Unlike net income (earnings), revenue does not subtract operating costs, taxes, or other charges. Figures are in USD; chart and tables below use historical filings.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Pfizer (PFE) revenue is $62.58B – edged down 1.6% year-over-year.
Pfizer revenue has grown on net over the period, with a +8.5% compound annual growth rate over 2020–2025 (5 years).
Between 2022 and 2025, Pfizer revenue plunged 37.6%, falling from $100.33B to $62.58B.
2022 marks the peak revenue at $100.33B, with the historical low of $4.02B recorded in 1985.
Pfizer Revenue by Year
Pfizer Revenue 2025: $62.58B
In 2025, Pfizer reported revenue of $62.58B, edged down 1.6% below 2024.
Pfizer Revenue 2024: $63.63B
Pfizer revenue in 2024 was $63.63B, grew 6.8% from 2023.
Pfizer Revenue 2023: $59.55B
2023's revenue for Pfizer came in at $59.55B, plunged 40.6% below 2022.
Pfizer Revenue 2022: $100.33B
Pfizer posted revenue of $100.33B in 2022, grew 23.4% from 2021. This figure represents the highest annual value in the available history.
Pfizer Revenue 2021: $81.29B
Pfizer revenue in 2021 was $81.29B.
See more financial history for Pfizer (PFE).
Sector peers by Revenue
Healthcare peers of Pfizer (PFE), ranked by their latest revenue
| $447.57B | |
| $94.19B | |
| $65.18B | |
| $64.93B | |
| $61.16B | |
| $58.74B | |
| $48.18B | |
| $36.74B |
- $447.57B
- $94.19B
- $65.18B
- $64.93B
- $61.16B
- $58.74B
- $48.18B
- $36.74B
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation